Raloxifene
Benzothiophene SERM; no endometrial agonist activity
Mechanism of Action
Raloxifene is a second-generation benzothiophene-class SERM that functions as an estrogen receptor antagonist in breast and uterine tissue while acting as an agonist in bone. Unlike triphenylethylene SERMs (tamoxifen, clomiphene), raloxifene does not exhibit partial agonist activity in endometrial tissue, significantly reducing endometrial proliferation risk. It maintains bone mineral density via ER agonism in osteoblasts/osteoclasts and improves lipid profiles. Raloxifene is studied for osteoporosis prevention, breast cancer risk reduction, and as an alternative to tamoxifen for gynecomastia prevention with improved endometrial safety.
Evidence Chain
Raloxifene
COMPOUND
2 Research Goals
• Anti-Aging & Longevity
• Sexual Health & Libido
Evidence Strength
4 articles sourced
Knowledge Graph
(6 connections)Research Goals
(2)Research Evidence
(4)Clomiphene Citrate: Evidence-Based Research Review
Clomiphene citrate (CC) is a non-steroidal triphenylethylene derivative classified as a Selective Estrogen Receptor Modulator (SERM). Originally developed for the induction of ovulation in women with anovulatory infertility, it has become a cornerstone of reproductive medicine. CC operates as a race
Raloxifene: Evidence-Based Research Review
Raloxifene is a second-generation selective estrogen receptor modulator (SERM) of the benzothiophene class. Developed to address the limitations of first-generation SERMs like tamoxifen, raloxifene exhibits distinct tissue-specific effects: it acts as an estrogen receptor (ER) agonist in bone and li
Raloxifene vs Tamoxifen: Evidence-Based Comparison
Selective Estrogen Receptor Modulators (SERMs) are a class of compounds characterized by their ability to act as estrogen receptor (ER) agonists or antagonists in a tissue-specific manner. Tamoxifen, a first-generation triphenylethylene SERM, and Raloxifene, a second-generation benzothiophene SERM,
Drostanolone Propionate: Evidence-Based Research Review
Drostanolone propionate (2α-methyl-5α-androstan-17β-ol-3-one propionate) is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Originally developed for the treatment of advanced breast cancer in postmenopausal women, it is characterized by its inability to aromatiz
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Highest Compatibility
Raloxifene + Kisspeptin
High Compatibility
Shared targets: estrogen receptor alpha (erα), estrogen receptor beta (erβ)
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.